Bioethics News

The Price of Health: The Cost of Developing New Medicines

March 31, 2016

(The Guardian) – When it comes to pharmaceutical companies, two accusations crop up time and again. One is that they charge too much for drugs and the other is that they focus research on diseases they can profit from. That means they concentrate on chronic diseases, rather than less profitable infectious ones. “If you make a drug for diabetes, the patient has to take that drug once a day for the rest of their lives. What you’re trying to do with an infectious disease is cure it within three to five days, so your treatment has to be short and cheap,” explains Simon Croft, professor of parasitology at the London School of Hygiene and Tropical Medicine.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.